AI Diagnostics
From the newsletter
The largest funding for health technology startups in April went to developing disease diagnostics for underserved communities, with a major focus on AI-powered TB diagnostics. A total of three companies, Reme-D, AI Diagnostics and Biovana, raised $5.9 million in funding with $5.7 million invested in disease diagnostics production.
AI Diagnostics raised $5.2 million, the highest funding in this round, to develop AI-powered TB diagnostics that enable frontline screening without specialist equipment.
Reme-D followed with a $0.5 million to develop and manufacture disease diagnostic testing systems that are suited for use in low resource settings. Biovana raised $0.2 million to support its health data system.
More details
Funding in April was distributed across three regions: Northern Africa, Southern Africa, and Western Africa. The largest allocation went to Southern Africa through AI Diagnostics in South Africa, which raised $5.2 million in a pre-Series A round. Northern Africa followed through Reme-D in Egypt, which secured $0.5 million in venture funding while Western Africa recorded the smallest share via Biovana in Nigeria, which raised $0.2 million.
AI Diagnostics, based in South Africa, raised $5.2 million in a pre-Series A round led by Global Innovation Fund, alongside iFSP Group, Africa Health Ventures, Savant Fund Manager and Steele Foundation for Hope. The funding is aimed at scaling its AI-powered digital stethoscope for tuberculosis screening, which enables low-cost and rapid TB detection in frontline and low-resource healthcare settings.
Reme-D, based in Egypt, raised $0.5 million in a venture round backed by the Global Innovation Fund to scale its diagnostic testing systems designed for low-resource healthcare environments. The company focuses on improving the speed and accuracy of disease detection through affordable, field-appropriate technologies, aiming to reduce diagnostic delays.
Biovana, based in Nigeria, raised $0.2 million in a venture round from Madica to build a federated biobank and health data infrastructure platform for African biomedical research. The funding supports development of its BioVana Index, which enables ethical, sovereign access to African biospecimens and datasets, linking certified biobanks with global research networks while keeping data control within the continent.
Our take
Frontline TB screening remains slow in underserved communities leading to spread of infections. Investment in non-invasive, rapid tools is therefore a clear systems win.
The value of investing in AI-powered TB diagnostics lies in cutting diagnostic delays and enabling earlier intervention.